Antibiotics: A Global Strategic Business Report
San Jose, CA (Vocus) October 25, 2010
The antibiotics market is witnessing an increase in the number of new product innovations, due to huge amount of money being invested in the R&D activity. Growth in the market is forecast to be driven by various emerging regulatory trends aimed at controlling the problem of antibiotic resistance. Restricting the use of those drugs posing serious resistance issues is bound to have an advantageous impact, since proliferation of new antibiotics would encourage growth in the market. In addition, emerging classes of drugs entering the market are offsetting lackluster growth in the antibiotics market. A variety of new drugs with improved effectiveness and reduced resistance have already made a foray into the market, while several others are in the pipeline. Bright spots in an otherwise lackluster antibiotics market include glycopeptides (Vancomycin, Teicoplanin) and Oxazolidinones (Pfizer’s Zyvox).
The global anti-infectives market is set to grow, riding on the gains made by anti-viral and anti-bacterial sectors. Such a scenario allows worldwide pharmaceutical firms to expand their operations, particularly in high-growth markets. Demand for anti-bacterials across the world is witnessing a steady growth. A constant rise in elderly population has contributed substantially to the rising severity and incidence of bacterials infections among the populace. Of the total affected population, nearly one-fifth of the patients suffer from hospital-acquired infections. In the US alone, about 90 thousand people die each year due to such infections. The growing resistance of pathogens, leading to virulent forms of infection that are difficult to treat, further complicates the situation.
Despite the growth trends anticipated for the global antibiotics market, its long-term success is primarily impacted by two key factors - antibiotic resistance and generic competition. Antibiotic resistance, which compels reduction in the usage of antibiotics, represents the primary market inhibitor. Increasing resistance even to strong antibiotics is resulting in incurable diseases. One of the major drawbacks of the industry is the inability to discover completely new antibiotics – so far only antibiotics discovered few decades ago have been modified to produce new generic forms. In recent times, there has been a decline in antibiotic prescriptions for respiratory related infections. Another factor that could have a strong bearing on the market over the next five to seven years is the rising generic competition. Market for antibacterial drugs is forecast to experience restricted growth as a result of patent expiries of antibiotic products from leaders such as Abbott, AstraZeneca, Johnson & Johnson, Merck, and Wyeth. In order to remain competitive in the market, many companies are engaged in the development of anti-MRSA treatments, which can also be used with traditional antibiotics. The market would also witness the introduction of many antibiotic products, which are currently in the clinical trial stage. One of the major causes for the increasing antibiotic-resistance is the inappropriate usage of antibiotics. Several doctors tend to prescribe antibiotic drugs to cure viral infections, making them ineffective against other related infections.
The US is the single largest market for Antibiotics, trailed by Europe and Asia-Pacific, as stated by the new market research report on Antibiotics. Asia-Pacific, driven by India and China also represents the most promising market, slated to expand at the overall highest compounded growth rate through 2015.
Other Antibiotics represents the largest and fastest product segment in the worldwide antibiotics market. The segment comprises of new drug classes such as Aminoglycosides, Tetracyclines, Sulfonamides and other future product launches. The market is also forecast to grow at the healthiest and fastest CAGR for the assessment years 2007-2015. In terms of sheer size, Cephalosporin and Quinolones make up the other significant product segments.
The global Antibiotics market is highly competitive, with major players competing fiercely with each other as well as with generic companies. Companies’ success largely depends on blockbuster drugs with proven effectiveness against bacteria and lesser resistance. Major market participants include Abbott Laboratories, Astellas Pharma, Inc, Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd, LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc, Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd and Toyama Chemical Co., Ltd.
The report titled “Antibiotics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of industry overview, market dynamics, competition, research findings, FDA approvals/patents, recent industry activity, and profiles of market players worldwide. Analysis and overview is presented for major geographic markets such as US, Canada, Japan, Europe, Asia-Pacific and Rest of World. Market analytics are provided in terms of dollars (value) for product segments including Penicillin, Cephalosporin, Macrolide, Quinolones, Carbapenems and Other Antibiotics. The study also presents historic data for an insight into market evolution over the period 2000 through 2006.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/